<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> is a thrombophilic condition marked by antibodies that recognize anionic <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-protein cofactor complexes </plain></SENT>
<SENT sid="1" pm="."><plain>We recently reported that exposure to IgG fractions from antiphospholipid patients reduces the level of annexin-V, a <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> protein, on cultured trophoblasts and endothelial cells and accelerates coagulation of plasma exposed to these cells </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we asked whether <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> might directly reduce annexin-V binding to noncellular <z:chebi fb="0" ids="16247">phospholipid</z:chebi> substrates </plain></SENT>
<SENT sid="3" pm="."><plain>Using ellipsometry, we found that antiphospholipid IgGs reduce the quantity of annexin-V bound to <z:chebi fb="0" ids="16247">phospholipid</z:chebi> bilayers; this reduction is dependent on the presence of beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I </plain></SENT>
<SENT sid="4" pm="."><plain>Also, exposure to plasmas containing <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> reduces annexin-V binding to <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> serine-coated microtiter plates, frozen thawed washed platelets, activated partial thromboplastin time (aPTT) reagent and prothrombin time reagent and reduces the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> effect of the protein </plain></SENT>
<SENT sid="5" pm="."><plain>These studies show that <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> interfere with the binding of annexin-V to anionic <z:chebi fb="0" ids="16247">phospholipid</z:chebi> and with its <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity </plain></SENT>
<SENT sid="6" pm="."><plain>This acceleration of coagulation, due to reduced binding of annexin V, stands in marked contrast to the "<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> effect" previously described in these patients </plain></SENT>
<SENT sid="7" pm="."><plain>These results are the first direct demonstration of the displacement of annexin-V and the consequent acceleration of coagulation on noncellular <z:chebi fb="0" ids="16247">phospholipid</z:chebi> surfaces by <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
</text></document>